Pompe Disease Therapeutics Market Set to Witness Growth Rate Owing to the Launch of Novel Treatment Therapies by key Market Players – Sanofi, Amicus, Valerion, Astellas, Roche, Lacerta, and others

DelveInsight’s Pompe Disease Market Insights Report offers a detailed analysis of disease, its causes, symptoms, diagnostics modalities, and treatment options. The report also offers comprehensive insights into Pompe Disease market size, epidemiology, emerging therapies, market drivers, market barriers, ongoing clinical trials, key collaboration in the space, and key pharmaceutical companies actively pushing the growth of market size forward. 

Some of the key highlights from the Pompe Disease Market Insights: 

• As per Delveinsight’s estimates, a total of 12,790 Pompe disease cases were reported in 2020.
• Among the EU5 countries, Germany had the highest prevalent population of Pompe Disease with 821 cases, followed by France, which had a prevalence of 689 cases, in 2020. On the other hand, Spain had the lowest prevalent population of 505 cases in 2020.
• In 2020, the prevalent cases of Infantile-onset Pompe Disease and Late-onset Pompe Disease in Japan were found to be 151 and 926 respectively, and are expected to increase by 2030.
• Some of the key pharma and biotech companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. 
• At present, the key market players in the Pompe Disease therapeutics domain include Sanofi, Actus, Amicus, Roche, and others 
• The launch of emerging therapies such as Avalglucosidase alfa, AT-GAA, ACTUS-101, and others is expected to enhance the treatment outcomes in Pompe patients.

Learn more by requesting for sample @ Pompe Disease Market Landscape 

Pompe Disease: Overview 

Pompe disease is a rare disease, in which a sugar molecule called glycogen builds up in the body’s cells. The buildup affects the working of different organs and tissues (but more often in the heart, respiratory, and skeletal muscles) The symptoms may occur at any age from birth to late adulthood. It is prevalent in various populations and ethnic groups worldwide and its incidence varies among different ethnic groups. As per the NORD, its incidence is approximately 1 in 40,000 births in the United States (and in the Netherlands). 

For more insights into Disease, causes, and treatment, reach out @ Pompe Disease Treatment Landscape 

Pompe Disease Epidemiology Segmentation

The Pompe Disease Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Total Live Birth Cases of Pompe Disease
• Total Adult Prevalent Cases of Pompe Disease
• Total Prevalent Cases of Pompe Disease
• Prevalence of Pompe Disease by Onset Types
• Incidence of IOPD based on Clinical Phenotype

Visit for more @ Pompe Disease Epidemiological Insights 

Pompe Disease Market

At present, there is no cure for Pompe disease, however, treatment options are available to address the symptoms. The affected individual is treated by a team of specialists (such as cardiologists, neurologists, and respiratory therapists). Supportive Care had been the mainstay of treatment for Pompe disease. However, after the approval of Enzyme replacement therapy (ERT), the treatment landscape has changed significantly. 

As per the DelveInsight, the improvement in the diagnosis methodologies, rising awareness of the diseases, incremental healthcare spending across the world, and estimated launch of emerging therapies will change the dynamics of the market in the coming years.

Pompe Disease Pipeline Therapies and Key Companies 

• Avalglucosidase alfa: Sanofi
• AT-GAA: Amicus Therapeutics
• ACTUS-101: Actus Therapeutics
• VAL-1221: Valerion Therapeutics
• AT845: Astellas Therapeutics
• SPK-3006: Roche
• AAV9: Lacerta Therapeutics

For more information, visit Pompe Disease Market Analysis, Patient Pool, and Emerging Therapies 

Pompe Disease Market Drivers 

• Upcoming therapies
• Side effects of existing therapies
• Improved disease understanding

Scope of the Report

• 11 Years Forecast
• 7MM Coverage 
• Descriptive overview of Pompe Disease, covering causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
• Comprehensive insight into Pompe Disease epidemiology and treatment in the 7MM
• Current and emerging therapies for Pompe Disease 
• Pompe Disease market drivers and barriers 

Key Questions Answered in the Report

• What was the Pompe Disease market share (%) distribution in 2018 and how it would look like in 2030?
• What would be the Pompe Disease total market size as well as market size by therapies across the 7MM during the forecast period (2018-2030)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Pompe Disease market size during the forecast period (2018-2030)?
• At what CAGR, the Pompe Disease market is expected to grow in 7MM during the forecast period (2018-2030)?

Get in touch with our Business executive @ Pompe Disease Market Landscape Analysis 

Table of Contents 

Learn more about the report offerings @ Pompe Disease Market Outlook

Related Reports –

• Pompe Disease Epidemiology Forecast

DelveInsight’s Pompe Disease – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Pompe Disease in the seven major markets (i.e. the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• Pompe Disease Pipeline Insights

Pompe Disease Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Pompe Disease market.

Latest Rare Disease Reports By DelveInsight –

• Complement 3 Glomerulopathy (C3G) Market

DelveInsight’ s “Complement 3 Glomerulopathy (C3G) Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Complement 3 Glomerulopathy (C3G) market forecast in the 7MM.

• Fragile X Syndrome (FXS) Market Insight

DelveInsight’ s “Fragile X Syndrome (FXS) Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Fragile X Syndrome (FXS) market forecast in the 7MM.

• Neurofibromatosis Type-2 Market Insights

DelveInsight’ s “Neurofibromatosis Type-2 Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Neurofibromatosis Type-2 market forecast in the 7MM.

• Argininosuccinic Aciduria Market Insights

DelveInsight’ s “Argininosuccinic Aciduria Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Argininosuccinic Aciduria market forecast in the 7MM.

• Porphyria Market Insight

DelveInsight’ s “Porphyria Market Insights, Epidemiology, and Market Forecast 2030” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Porphyria market forecast in the 7MM.

Healthcare Blogs –

• Rare Disease Market Drivers
• Challenges in the Rare Disease Market
• Rare Diseases Pipeline Therapies
• Progeria Market 
• Angelman Syndrome Market Analysis

Get in touch with our Business executive for Competitive Intelligence Services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Information:

Shruti Thakur
info@delveinsight.com
+1(919)321-6187